List view / Grid view
Acquisition of the US biotech gives Johnson & Johnson rights…
Acquisition of the US biotech gives Johnson & Johnson rights to clinical-stage precision treatments for solid tumours.
The innovation is set to change how eligible bladder cancer…
The innovation is set to change how eligible bladder cancer patients in the US are treated who are unresponsive to traditional therapy.
As part of EPR’s Women in Pharma series, Catherine Owen,…
As part of EPR’s Women in Pharma series, Catherine Owen, President of Infectious Disease and Vaccines at Johnson & Johnson, talks to Science Editor Dr Zara Kassam about keeping up with the competition, innovation and grasping the breadth of business...
